Pre-made Lesofavumab benchmark antibody ( Whole mAb, anti-Influenza B Virus therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-305

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-305 Category Tag

Product Details

Pre-Made Lesofavumab biosimilar, Whole Mab: Anti-Influenza B Virus therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lesofavumab is a human immunoglobulin G1, antibody cloned from a single human plasmablast, isolated from an influenza-vaccinated donor.

Products Name (INN Index)

Pre-Made Lesofavumab biosimilar, Whole Mab: Anti-Influenza B Virus therapeutic antibody

INN Name

Lesofavumab

Target

Influenza B Virus

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2016

Companies

Genentech

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Influenza B virus infections

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

Influenza B Virus

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide